Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOSYN-RF 5.2% vs AMINOSOL 5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.
Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.
Parenteral nutrition in patients with acute or chronic renal failure to minimize nitrogen accumulation,Adjunct to dialysis to correct amino acid deficiencies,Off-label: Hypercatabolic states with renal compromise
Total parenteral nutrition in patients with inadequate oral or enteral intake,Correction of negative nitrogen balance in malnourished patients
1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 m L to 1000 m L/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.
Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.
The terminal elimination half-life of infused amino acids is approximately 10–20 minutes, reflecting rapid distribution and metabolism; clinical context: continuous infusion maintains steady state within 30 minutes.
The half-life of infused amino acids is not defined as they are endogenous compounds. However, the nitrogen from amino acids has a biological half-life of approximately 6-18 hours, depending on metabolic activity. As part of total parenteral nutrition, the elimination half-life of infused amino acids is influenced by protein turnover and catabolism.
Amino acids undergo hepatic deamination and transamination; nitrogen is converted to urea via the urea cycle (hepatic) and excreted renally. The product's composition aims to reduce ureagenesis.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Excretion of nitrogenous waste as urea occurs renally.
Primarily renal; >95% of infused essential amino acids and small peptides are reabsorbed; excess amino acids are deaminated and nitrogen excreted as urea in urine (renal clearance of urea). Biliary/fecal excretion is negligible (<2%).
Excretion of infused amino acids is primarily renal, with small amounts lost via feces and skin. Approximately 85-95% of the nitrogen load is excreted in urine as urea, ammonia, and other nitrogenous wastes. Less than 5% is eliminated in feces.
Amino acids show minimal protein binding (<5%); not bound to albumin or globulins to a significant extent.
Amino acids are not protein-bound; they exist free in plasma. Minimal reversible binding to albumin occurs for some amino acids, but overall binding is <10%.
Approximately 0.2–0.3 L/kg, reflecting distribution mainly into extracellular fluid and lean tissues; total body water is about 0.6 L/kg, but amino acids are rapidly taken up by cells.
The volume of distribution for amino acids is approximately 0.3-0.4 L/kg, reflecting distribution primarily in extracellular fluid and to a lesser extent intracellularly.
Intravenous: 100% (complete bioavailability); not absorbed orally or via other routes.
Intravenous: 100% bioavailability. Not administered via other routes; oral or enteral administration is not applicable due to hepatic first-pass metabolism and different pharmacokinetics.
For GFR < 25 m L/min: reduce dose to 0.5-0.8 g/kg/day and monitor BUN and electrolytes. In patients on dialysis, provide 1.0-1.2 g/kg/day postpartum. Not recommended with GFR < 15 m L/min unless on renal replacement therapy.
In GFR < 50 m L/min: reduce infusion rate by 50% and monitor nitrogen balance. In ESRD on dialysis: use only if essential; typical dose 0.5-0.6 g/kg/day of amino acids with careful monitoring.
Child-Pugh Class B or C: avoid use due to risk of hyperammonemia and encephalopathy. For mild impairment, use with caution and monitor ammonia levels; dose reduction may be needed.
Contraindicated in severe hepatic failure (Child-Pugh C) due to risk of hepatic encephalopathy. In Child-Pugh A or B, use with caution and reduce dose by 30-50%; monitor ammonia levels.
Neonates and infants: 1.5-3.0 g/kg/day intravenously. Children: 1.0-2.0 g/kg/day. Adjust based on metabolic requirements and tolerance. Administer as part of parenteral nutrition.
Infants and children: 1-2 g/kg/day of amino acids via total parenteral nutrition (TPN) as a 5% solution. Adjust based on age, weight, and clinical condition. Maximum infusion rate 0.1 g/kg/hour.
Initiate at lower end of dosing range (1.0-1.2 g/kg/day) due to decreased renal function. Monitor serum creatinine and fluid balance. Adjust as needed.
Start at lower end of dosing; monitor renal function (creatinine clearance) and avoid fluid overload. Typical initial dose: 0.8-1 g/kg/day of amino acids, adjusted to tolerance and clinical response.
Not for intravenous administration to patients with inborn errors of amino acid metabolism, severe hepatic failure, or hemodialysis-dependent patients with hyperammonemia.
None.
Monitor serum electrolytes, acid-base balance, and renal function closely; risk of hyperkalemia, hyperammonemia, and fluid overload; not indicated for anuric patients not on dialysis; use with caution in patients with hepatic impairment.
Use with caution in patients with renal impairment (risk of azotemia and electrolyte imbalances),Monitor serum electrolytes, blood glucose, and fluid balance regularly,Risk of hyperglycemia in diabetic patients; adjust insulin accordingly,Possible hyperammonemia, especially in patients with hepatic insufficiency,Contains aluminum; may accumulate in renal impairment, leading to osteomalacia or neurotoxicity
Severe hepatic failure, hyperammonemia, anuria without dialysis support, inborn errors of amino acid metabolism, known hypersensitivity to components.
Severe hepatic failure with encephalopathy,Severe uremia without dialysis,Inborn errors of amino acid metabolism,Hypersensitivity to any component
Patients receiving Aminosyn-RF 5.2% are typically on a protein-restricted diet. Concurrent oral intake of high-protein foods or supplements may increase nitrogen waste and should be avoided unless prescribed. Limited fluid intake may be necessary. Consult a renal dietitian for specific dietary adjustments.
No direct food interactions as Aminos 5% is administered intravenously. However, oral dietary intake must be coordinated with total parenteral nutrition to avoid excessive protein or electrolyte intake.
Aminosyn-RF 5.2% is an amino acid solution used for parenteral nutrition. There are no adequate studies in pregnant women. Animal reproduction studies have not been conducted. Theoretical risks include amino acid imbalances affecting fetal development if maternal nutrition is compromised. Generally, IV amino acids are used during pregnancy only if clearly needed, and benefits may outweigh risks in malnourished mothers. First trimester: avoid unless essential. Second/third trimester: use with caution, monitor fetal growth. Peripartum: risk of maternal fluid/electrolyte imbalances affecting fetus.
Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with Aminosol 5%. Therefore, the teratogenic risk is not well defined. However, as a component of parenteral nutrition, it is considered essential for maternal and fetal health when indicated. Use only if clearly needed, weighing potential benefits against unknown risks. No specific trimester-associated risks have been reported.
Amino acids are endogenous substances normally present in breast milk. Exogenous administration would mix with maternal pool. No specific data on M/P ratio. Likely excreted into milk but considered compatible with breastfeeding at usual doses. Caution if maternal renal function impaired, as metabolite accumulation may occur. Monitor infant for rare metabolic disturbances.
Aminosolic 5% is a mixture of amino acids naturally present in human milk. Administration to lactating women may result in excretion of amino acids into breast milk, but the amounts are unlikely to be clinically significant. The M/P ratio is not known. Caution is advised, but use is generally considered compatible with breastfeeding when clinically indicated.
Pregnancy increases plasma volume and renal blood flow, potentially altering amino acid clearance. Doses should be based on maternal weight and nutritional needs, with close monitoring of nitrogen balance. Possibly lower doses in early pregnancy due to nausea. No specific PK studies; clinical monitoring of labs is essential for dose titration.
Standard adult dosing (5% solution, 500-1000 m L/day) may be used; however, increased fluid volume and metabolic demands in pregnancy may require dose adjustments. Monitor for fluid overload and adjust infusion rate accordingly. No specific dose adjustment recommendations are established; use caution and individualize based on clinical status.
Aminosyn-RF 5.2% is a renal-specific amino acid solution containing essential amino acids and histidine, designed for patients with acute or chronic renal failure to reduce nitrogen load. Monitor serum electrolytes, BUN, creatinine, ammonia, and acid-base status. Use with caution in patients with metabolic acidosis or hyperammonemia. Do not administer simultaneously with blood products via same IV line. Ensure adequate caloric intake to prevent utilization of amino acids for energy.
Aminos 5% is a crystalline amino acid solution used for parenteral nutrition. In renal failure, adjust dose to limit nitrogen load; monitor BUN. In hepatic encephalopathy, consider branched-chain amino acid formulations. Do not administer concurrently with blood products through same IV line due to risk of agglutination. Infuse via central line if peripheral veins insufficient; peripheral administration requires adequate lipid-based calorie co-administration to prevent phlebitis.
This medication is a sterile amino acid solution given intravenously to provide protein for patients with kidney problems.,It is usually administered in a hospital setting under close medical supervision.,Your healthcare team will monitor your kidney function, electrolyte levels, and other lab values regularly.,Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing) or infusion site reactions immediately.,This solution does not contain all necessary nutrients; you may require additional supplements or a special diet.
This solution provides essential building blocks (amino acids) for protein synthesis when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or drainage.,Tell your doctor if you experience nausea, vomiting, or headache; dose adjustment may be needed.,Do not abruptly stop this infusion; it is part of your total nutrition plan.,Regular blood tests will be required to monitor kidney and liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOSYN-RF 5.2% vs AMINOSOL 5%, answered by our medical review team.
AMINOSYN-RF 5.2% is a Parenteral Nutrition Solution that works by Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.. AMINOSOL 5% is a Parenteral Nutrition Solution that works by Aminosyl 5% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral feeding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOSYN-RF 5.2% and AMINOSOL 5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOSYN-RF 5.2% is: 1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 m L to 1000 m L/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.. The standard adult dose of AMINOSOL 5% is: Intravenous infusion: 500 m L to 1 L of 5% solution over 8-12 hours, providing 25-50 g of amino acids. Maximum infusion rate: 0.1 g/kg/hour. Dose based on metabolic requirements and clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOSYN-RF 5.2% and AMINOSOL 5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOSYN-RF 5.2% is classified as Category C. Aminosyn-RF 5.2% is an amino acid solution used for parenteral nutrition. There are no adequate studies in pregnant women. Animal reproduction studies have not been conducted. Theo. AMINOSOL 5% is classified as Category C. Aminosol 5% is a crystalline amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies hav. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.